An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 22 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2018.
- 22 Sep 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2018.